Atorvastatin group (n = 40) | Placebo group (n = 38) | Difference between groups after 12 weeks | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | 12 weeks | Mean difference (95% CI) | Effect size (95% CI) | Baseline | 12 weeks | Mean difference (95% CI) | Effect size (95% CI) | Mean difference (95% CI) | Effect size (95% CI) | p value | |
WBC (× 103 cells/ml) | 7.6 ± 2.5 | 7.4 ± 1.8 | 0.01 (− 0.6, 0.63) | 0.007 (− 0.42, 0.43) | 6.7 ± 1.7 | 6.7 ± 1.5 | − 0.01 (− 0.45, 0.41) | − 0.01 (− 0.35, 0.33) | − 0.03 (− 0.8, 0.7) | 0.01 (− 0.42, 0.46) | 0.93 |
IL-6 (pg/ml) | 0.92 ± 0.87 | 0.69 ± 0.7 | 0.2 (− 0.05, 0.5) | 0.15 (− 0.15, 0.46) | 1.1 ± 1.3 | 0.46 ± 0.3 | 0.6 (0.2, 1.05) | 0.64 (0.43, 0.86) | 0.4 (− 0.09, 0.9) | − 0.36 (− 0.81, 0.08) | 0.07 |
TNF-α (pg/ml) | 2.1 ± 0.4 | 2.2 ± 0.3 | − 0.07 (− 0.2, 0.07) | − 0.19 (− 0.27, − 0.11) | 1.9 ± 0.3 | 2.2 ± 0.4 | − 0.2 (− 0.34, − 0.06) | − 0.55 (− 0.63, − 0.47) | − 0.13 (− 0.3, 0.07) | 0.29 (− 0.15, 0.74) | 0.20 |
HsCRP (ng/ml) | 5.35 ± 3.2 | 5.49 ± 3.4 | − 0.1 (− 1.2, 0.9) | − 0.04 (− 0.76, 0.67) | 4.10 ± 2.9 | 4.45 ± 3.2 | − 0.3 (− 1.4, 0.8) | − 0.11 (− 0.78, 0.55) | − 0.2 (− 1.7, 1.3) | 0.06 (− 0.38, 0.5) | 0.78 |
Procalcitonin (pg/ml) | 0.043 ± 0.18 | 0.04 ± 0.15 | 0.003 (− 0.02, 0.03) | 0.01 (− 0.02, 0.05) | 0.038 ± 0.07 | 0.02 ± 0.05 | 0.02 (− 0.001, 0.04) | 0.3 (0.29, 0.32) | 0.02 (− 0.01, 0.05) | − 0.22 (− 0.67, 0.21) | 0.15 |
CAT score | 29.4 ± 7 | 22 ± 5.6 | 7.8 (5.3, 10.3) | 1.3 (− .005, 2.6) | 28.1 ± 6 | 19.6 ± 7.2 | 8.4 (6.4, 10.4) | 1.25 (− 0.26, 2.78) | 0.57 (− 2.5, 3.7) | − 0.09 (− 0.53, 0.35 | 0.71 |
Cholestrol (mg/dl) | 206 ± 42 | 160 ± 44 | 42 (29, 55) | 1.03 (− 8.6, 10.6) | 211 ± 85 | 180 ± 31 | 18 (9.3, 27) | 0.56 (− 7, 8.1) | − 24 (− 39.5, − 8.7) | 0.7 (0.24, 1.15) | 0.003 |
Low-density lipoprotein (mg/dl) | 124 ± 33 | 100 ± 37 | 22 (10, 33) | 0.61 (− 6.8, 8.1) | 119 ± 30 | 116 ± 24 | 3.6 (− 4.2, 11.5) | 0.11 (− 5.7, 6.01) | − 18 (− 31.6, − 4.7) | 0.58 (0.13, 1.04) | 0.009 |